Literature DB >> 21707577

Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements.

Mark W Skinner1.   

Abstract

For nearly 50 years, the goal of the World Federation of Hemophilia (WFH) has been to achieve 'Treatment for All' patients with inherited bleeding disorders, regardless of where they live. With proper diagnosis, management and care, people with bleeding disorders can live perfectly healthy lives. Without treatment, the reality is that many will die young or, if they survive, suffer joint damage that leaves them with permanent disabilities. Only about 25% of the estimated 400 000 people with haemophilia worldwide receive adequate treatment. The percentage is far lower for those with von Willebrand Disease (VWD) and the rarer bleeding disorders. The achievements of the WFH to close the gap in care for people with bleeding disorders are measureable over time by using three key indicators; the difference in the estimated and actual number of people known with bleeding disorders, the amount of treatment products needed versus that available, and the number of people born with bleeding disorders and the number who reach adulthood. There are five essential elements to achieve a sustainable national care programme: ensuring accurate laboratory diagnosis, achieving government support, improving the care delivery system, increasing the availability of treatment products, and building a strong national patient organization.
© 2011 Blackwell Publishing Ltd.

Entities:  

Keywords:  Treatment for All; WFH Global Survey; World Federation of Hemophilia; bleeding disorders; haemophilia

Mesh:

Substances:

Year:  2011        PMID: 21707577     DOI: 10.1111/j.1365-2141.2011.08765.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  Present and future challenges in the treatment of haemophilia: the patient's perspective.

Authors:  Romano Arcieri; Angelo C Molinari; Stefania Farace; Giuseppe Mazza; Alberto Garnero; Gabriele Calizzani; Paola Giordano; Emily Oliovecchio; Lorenzo Mantovani; Lamberto Manzoli; Paul Giangrande
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 2.  The demand for factor VIII and for factor IX and the toll fractionation product surplus management.

Authors:  Gabriele Calizzani; Samantha Profili; Fabio Candura; Monica Lanzoni; Stefania Vaglio; Livia Cannata; Giancarlo M Liumbruno; Massimo Franchini; Pier Mannuccio Mannucci; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

3.  Equitable Access to Gene Therapy: A Call to Action for the American Society of Gene and Cell Therapy.

Authors:  Kenneth Cornetta; Kirtika Patel; Christopher Mwaniki Wanjiku; Naftali Busakhala
Journal:  Mol Ther       Date:  2018-11-16       Impact factor: 11.454

4.  Successful esophagectomy in a patient with combined esophageal cancer and hemophilia B.

Authors:  Guo-Fei Zhang; Ying Chai; Wen-Shan Li; Lian-Sheng Huang; Gang Shen
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

5.  Gene therapy in hemophilia A: a cost-effectiveness analysis.

Authors:  Nicoletta Machin; Margaret V Ragni; Kenneth J Smith
Journal:  Blood Adv       Date:  2018-07-24

6.  Comparative Analysis of the Occurrence and Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Hemophilic Arthropathy and Osteoarthritis.

Authors:  Piotr Wojdasiewicz; Łukasz A Poniatowski; Andrzej Kotela; Marta Skoda; Michał Pyzlak; Aleksandra Stangret; Ireneusz Kotela; Dariusz Szukiewicz
Journal:  J Immunol Res       Date:  2020-08-20       Impact factor: 4.818

7.  Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B.

Authors:  Dawei Wang; Xiaohu Shao; Qiang Wang; Xiaohong Pan; Yujun Dai; Shuxian Yao; Tong Yin; Zhugang Wang; Jiang Zhu; Xiaodong Xi; Zhu Chen; Saijuan Chen; Guowei Zhang
Journal:  Clin Transl Med       Date:  2021-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.